A link between obesity and periodontitis has been suggested because of compromised immune response and chronic inflammation in obese patients. In this study, we evaluated the anti-inflammatory properties of Kavain, an extract from Piper methysticum, on Porphyromonas gingivalis–induced inflammation in adipocytes with special focus on peroxisome proliferation–activated receptor γ coactivator α (PGC-1α) and related pathways. The 3T3-L1 mouse preadipocytes and primary adipocytes harvested from mouse adipose tissue were infected with P. gingivalis, and inflammation (TNF-α; adiponectin/adipokines), oxidative stress, and adipogenic marker (FAS, CEBPα, and PPAR-γ) expression were measured. Furthermore, effect of PGC-1α knockdown on Kavain action was evaluated. Results showed that P. gingivalis worsens adipocyte dysfunction through increase of TNF-α, IL-6, and iNOS and decrease of PGC-1α and adiponectin. Interestingly, although Kavain obliterated P. gingivalis–induced proinflammatory effects in wild-type cells, Kavain did not affect PGC-1α–deficient cells, strongly advocating for Kavain effects being mediated by PGC-1α. In vivo adipocytes challenged with i.p. injection of P. gingivalis alone or P. gingivalis and Kavain displayed the same phenotype as in vitro adipocytes. Altogether, our findings established anti-inflammatory and antioxidant effects of Kavain on adipocytes and emphasized protective action against P. gingivalis–induced adipogenesis. The use of compounds such as Kavain offer a portal to potential therapeutic approaches to counter chronic inflammation in obesity-related diseases.
Periodontitis is an inflammatory disease of infectious origin adversely affecting tooth-supporting tissues that may lead to tooth loss. Such disease is common, and severe forms affect ∼10% of the world population (1). Several risk factors have been described, including smoking and systemic conditions. Among these, the role for overweight and obesity has been suggested, as increased body mass index and waist circumference are associated with periodontal disease worsening (2) and a reduced response to periodontal treatment in these individuals (3).
Several studies have explored the biological mechanisms underlying this association that may explain the aggravated periodontal destruction. Monocyte dysregulation, alteration of proinflammatory and anti-inflammatory cytokine secretion, and impaired clearance of keystone periodontal pathogens such as Porphyromonas gingivalis have been demonstrated (4). Bacterial spreading from the periodontal pocket to the bloodstream occurs, and sustained links between periodontitis and several systemic diseases, including atherosclerosis, rheumatoid arthritis, and diabetes, have been demonstrated (5, 6). For instance, P. gingivalis has been detected in vascular walls (7) and in inducing dysbiosis of gut microbiota (8).
In adipose tissue, impaired function of adipocytes is a key factor of obesity and type 2 diabetes and is sustained by more activated (M1) macrophages (9). Free fatty acid deposition within the adipose tissue alters adipose cell secretory functions, induces oxidative stress and reactive oxygen species (ROS) production, causes hypertrophy, and produces many vicious cytokines including TNF-α, IL-6, and chemokines, resulting in sustained chronic inflammation (10). Several exogenous stimuli, including infection and endotoxemia, contribute to this chronic inflammatory state as demonstrated by Mycobacterium tuberculosis, Escherichia coli, and P. gingivalis (11–13) through the activation of TLR-related pathways, nucleotide oligomerization domain (NOD)-like receptor platforms (NLRPs), and a concomitant reduction in adiponectin secretion (12, 14).
Kavain, an extract from the root of the Kava plant Piper methysticum exhibits anti-inflammatory properties by reducing TNF-α–induced pathophysiological conditions via downregulation of inflammatory factors such as NF-κB (15, 16). Kavain has been evaluated in the management of several inflammatory diseases, including periodontitis, in which Kavain and its derivative compound Kava-241 effectively reduced inflammatory cell infiltrate and alveolar bone loss in a P. gingivalis–induced periodontitis mouse model (17, 18). Anti-inflammatory properties were also observed in vitro in primary macrophages stimulated by E. coli LPS, (17) suggesting that Kavain has therapeutic potential in the management of chronic inflammatory disease. In the context of obesity, no data are actually available regarding the putative effect of Kavain on adipocyte maturation/differentiation and release of anti-inflammatory adiponectin and proinflammatory adipokines in such cells.
PGC-1α is a major regulator of several key components of the adipocyte functions and adaptive thermogenesis program, including the stimulation of energy uptake and fatty acid oxidation (19, 20). It is also considered as a major regulator of adipocyte browning and of thermogenic activation of brown fat after reduction of adipocyte hypertrophy, inflammation, and generation of ROS (21). Furthermore, mice lacking PGC-1α in adipose tissue fed a high-fat diet develop insulin resistance and increased circulating lipid levels (22). These data suggest that PGC-1α is a key moderator of energy metabolism and prevents the development of metabolic syndrome or type 2 diabetes mellitus (23–25). Interestingly, the impact of P. gingivalis on PGC-1α has not yet been described.
This study was designed to evaluate, in vitro and in vivo, the role of Kavain on key immunological mediator molecules associated with inflammation, oxidative stress, and lipid accumulation in adipocytes infected with P. gingivalis and the mechanisms involved, with the ultimate goal of improving periodontal disease management, thus reducing its social and financial costs. Furthermore, in the current study, we examined whether the Kavain-mediated attenuation of inflammatory adipokines after P. gingivalis infection is PGC-1α dependent.
Materials and Methods
Bacterial strain P. gingivalis ATCC 33277 (American Type Culture Collection, Manassas, VA) was cultured and maintained on enriched tryptic soy agar plates containing a mixture of defibrinated sheep blood, 5 mg/ml hemin, and 1 mg/ml menadione at 37°C under anaerobic conditions. Bacterial colonies were then transferred into Brain Heart Infusion Medium (Becton Dickinson, Sparks, MD) supplemented with the same materials. On the day of infection, bacteria were centrifuged and washed with PBS, and the number of bacteria was determined by measuring the OD at 600 nm as previously described (26).
3T3-L1–derived adipocyte cell culture
3T3-L1 mouse preadipocytes were obtained from American Type Culture Collection. The culture medium DMEM (PAN Biotech) contained 4.5 g/l glucose, 10% heat inactivated FBS (PAN Biotech), and 5 mM glutamin (PAN Biotech). The cells were cultured in a humidified 5% CO2 atmosphere at 37°C. For cell differentiation assay, preadipocytes were plated in six-well plates at a density of 125 × 103 cells per well and allowed to grow until confluence. One day after confluence (day 0), preadipocytes were exposed to the culture medium supplemented with insulin (1 mg/ml; Sigma-Aldrich), isobutyl-1-methylxanthine (500 mM; Sigma-Aldrich), and dexamethasone (0.25 mM; Sigma-Aldrich) until day 2. Then, insulin-containing medium was replaced every 2 d (23, 24). Adipocytes were infected with P. gingivalis at a multiplicity of infection of 25. Cells were collected on day 8 for analysis.
Primary adipocyte isolation and preparation for experiments
Mice adipose tissue was surgically removed and placed in sterile box. Isolation of primary adipocytes was performed according to Abcam Preadipocyte Isolation Kit (ab196988). Adipose tissue was minced with dissecting scissors in a sterile vessel for at least 5 min and placed into 1 ml of collagenase per 0.5 g of tissue and incubated in a heated orbital shaker at 37°C for 30 min at 160 rpm and then transferred to fresh preadipocyte medium (DMEM/F12, 10% FBS, penicillin/streptomycin, amphotericin B). Preadipocytes were kept for differentiation using a 3T3-L1 differentiation media. Cells were exposed to P. gingivalis as described above, and cells were collected on day 8 for analysis.
P. gingivalis–infected cells were treated on the day of infection with Kavain (MilliporeSigma) (25–150 μg/ml). Cells were collected on day 8 for analysis.
Generation of lentiviral vector–mediated, PGC-1α–deficient, 3T3-L1–derived adipocytes
SMARTvector Lentiviral shRNA-PPARGC1A or scrambled RNA (Dharmacon, Lafayette, CO) was applied to 3T3-L1 cells to establish a stably transduced cell line. Briefly, 1 × 106 cells were seeded in six-well plates 1 d prior to transduction. On the day of transduction, the transduction medium was made by 1 × 106 transducing units of lentiviral particles with 0.5 ml of α-MEM growth medium applied to each well and incubated for 3 h to maximize the contact between each cell and lentiviral particles. Cells were also treated with the transduction medium without lentiviral particles, which served as untransduced control. Growth medium (1.5 ml) was then added to each well in the presence of 8 μg/ml polybrene (final concentration). After 48 h incubation, antibiotic selection medium (α-MEM growth medium with 10 μg/ml puromycin) was used to kill all the untransduced cells. Cells were then cultured and maintained as outlined above (24, 27).
Analysis of intracellular ROS level
Intracellular ROS levels were measured by staining with 2′,7′-dichlorofluorescein diacetate (DCFH-DA; Sigma-Aldrich), which is a cell-permeable, nonfluorescent agent that can be deacetylated by intracellular esterases to form nonfluorescent DCFH. In the presence of ROS, DCFH is highly fluorescent DCF. On day 8 following infection, cells were incubated with 25 μM DCFH-DA for 30 min at 37°C, and fluorescence was observed at 200× magnification via fluorescence microscopy (28).
Real-time quantitative PCR
Total RNA was extracted from 3T3-L1 cells after 8 d of differentiation and exposure to P. gingivalis with TRIzol (Ambion, Austin, TX). A BioTek plate reader and the Take3 plate (BioTek, Winooski, VT) were used to determine RNA at an absorbance of 260 nm (A260). RNA measurements were subsequently evaluated by the A260/A280 ratio. A High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used to synthesize cDNA from total RNA (Applied Biosystems). TaqMan Fast Universal Master Mix (2×) on a 7500 HT Fast Real-Time PCR System (Applied Biosystems) was used to perform real-time PCR. Specific TaqMan Gene Expression Assay probes for mouse CEBPa, FAS, PPRY, TLR2, TLR4, TNF-α, CCL2, CCN3/nephroblastoma overexpressed (NOV), MYD88, NRLP3, NF-κB, iNOS, PGC-1α, HO-1, MnSOD, IL-6, adiponectin, NRLP2, NOD2, and GAPDH were used as previously described (25, 27, 29, 30).
Oil Red O staining
Staining was performed using 0.21% Oil Red O in 100% isopropanol (Sigma-Aldrich). Briefly, cells were fixed in 10% formaldehyde for an hour, stained with Oil Red O for 10 min, and rinsed with 60% isopropanol (Sigma-Aldrich). The Oil Red O was then eluted by adding 100% isopropanol for 10 min and the absorbance (OD) was measured at 490 nm. Lipid droplet accumulation was examined by using inverted multichannel (24).
Cells were fixed with 4% paraformaldehyde at room temperature for 10 min and washed three times with PBS. Samples were blocked and permeabilized in PBS containing 1% BSA and 0.5% Triton X-100 (Sigma-Aldrich) for 30 min at room temperature and incubated with the primary Ab diluted in PBS containing 1% BSA and 0.1% Triton X-100 overnight at 4°C in a moist chamber. Slides were washed three times with PBS, incubated with the secondary Ab diluted in PBS containing 1% BSA and 0.1% Triton X-100 at room temperature for 1 h, and washed with PBS for three times (31).
Western blot analysis
For Western blot, primary adipocyte cells were first lysed in radioimmunoprecipitation assay buffer supplemented with protease and phosphatase inhibitors (cOmplete Mini and PhosSTOP; Roche Diagnostics, Indianapolis, IN), and total protein content was analyzed by the Bradford method (Bio-Rad, Hercules, CA). Immunoblotting was performed for selected Anti–phospho-Insulin Receptor (IRp-Tyr972, catalog no. I1783 Sigma-Aldrich), total IR (catalog no. ab95231; Abcam), pAkt (S473) (catalog no. 9271; Cell Signaling Technology), and total Akt (catalog no. 9272; Cell Signaling) proteins as previously described (23, 25, 27, 32).
All animal experiments followed New York Medical College Institutional Animal Care and Use Committee institutionally approved protocol in accordance with the National Institutes of Health Guidelines. DIO-B6 mice from Taconic Biosciences were used in this study. Mice were divided into three groups: 1) wild-type (WT; untreated control), 2) mice infected with P. gingivalis, and 3) mice infected with P. gingivalis and treated with Kavain. A total of 5 × 108 CFU of live P. gingivalis suspended in 100 μl of PBS was injected i.p. three times a week for 1 wk. Kavain was given at the same time at the dose of 40 mg/kg. Mice were anesthetized with sodium pentobarbital (65 mg/kg, i.p.) and at the time of sacrifice, adipose tissue was collected. Adipose tissue was surgically removed and placed in sterile box. Isolation of primary adipocytes was performed according to Abcam Preadipocyte Isolation Kit (ab196988).
Statistical significance between experimental groups was determined by Student t test for pairwise comparison between groups or by ANOVA with Tukey–Kramer post hoc analysis for comparison between multiple groups. The data are presented as means ± SEM and the null hypothesis was rejected at p < 0.05.
Kavain counteracted increase of mRNA inflammatory gene expression induced by P. gingivalis in 3T3-L1–derived adipocyte cells and primary adipocytes
To evaluate the anti-inflammatory properties of Kavain on proinflammatory cytokines, real-time quantitative PCR was performed to examine mRNA expression levels of inflammatory cytokines. As expected, P. gingivalis infection significantly increased TNF-α expression in 3T3-L1–derived adipocyte cells (Fig. 1A). Treatment with Kavain reduced such increase for each dose tested (25–150 μg/ml), reaching a plateau at 50 μg/ml (Fig. 1A). Accordingly, the dose of 50 μg/ml was then selected for further experiments.
P. gingivalis also significantly increased mRNA expression levels of NF-κB, IL-6, CCL2, and CCN3/NOV compared with control (p < 0.05) (Fig. 1A–E). Treatment with Kavain prevented the induced inflammatory effects (p < 0.05) and reduced the expression of all markers (Fig. 1A–E). Such results were also confirmed in P. gingivalis–infected primary adipocytes harvested from mice and treated with Kavain (Fig. 2).
Kavain reduced the expression of adipogenic markers, oil droplet formation, and insulin resistance induced by P. gingivalis
P. gingivalis enhanced (p < 0.05) mRNA expression of adipogenic genes encoding CEBPα, FAS, and PPAR-γ in 3T3-L1–derived adipocyte cells. Kavain reduced the effects induced by the infection (p < 0.05) (Fig. 3A–C). Oil Red O staining demonstrated the increase of lipid droplet formation after exposure with P. gingivalis, and treatment with Kavain significantly (p < 0.05) prevented the lipid droplet formation after 8 d of differentiation (Fig. 3D–H).
It has been established that insulin receptor phosphorylation at tyrosine 972 activates and phosphorylates Akt at serine 473, thereby regulating metabolism and insulin-dependent gene expression. Interestingly, in isolated primary adipocytes, infection with P. gingivalis significantly decreased phosphorylation of both IRp972 and pAkt levels (p < 0.05), markers of insulin resistance. Kavain treatment was effective to overcome this effect and significantly (p < 0.05) induced expression of IRp972 and pAkt proteins (Fig. 2F, 2G).
Kavain reduced TLRs and NOD receptor mRNA expression in 3T3-L1–derived adipocyte cells
TLRs are well-described membrane receptors for pathogens. In adipocytes, P. gingivalis significantly increased mRNA expression of TLR2, TLR4, and adapter MyD88 (p < 0.05) (Fig. 1G–I). TLR activation was also associated with an increase of mRNA expression encoding for inflammasome platforms NOD2 and NLRP3 (Fig. 1J, 1K). Interestingly, Kavain reduced TLR2 and TLR4 expressions as well as NOD2 and NLRP3 (p < 0.05) (Fig. 1G–K) in infected cells, highlighting the ability of such compounds to reduce P. gingivalis–induced innate immune response.
Antioxidative properties of Kavain in 3T3-L1–derived adipocyte cells
Oxidative stress is a key component of obesity-associated tissue inflammation. P. gingivalis increased iNOS mRNA expression, resulting in increased intracellular ROS production (2.5-fold versus untreated cells; p < 0.05) (Fig. 4A, 4B). Kavain treatment reduced iNOS expression in infected cells but also displayed antioxidative properties by inducing a significant decrease in ROS production (p < 0.05) (Fig. 4A, 4B), confirming the beneficial effect of these compounds.
Kavain increased expression of PGC-1α, MnSOD, HO-1, and adiponectin
In 3T3-L1–derived adipocyte cells, P. gingivalis significantly reduced mRNA expression of PGC-1α, MnSOD, adiponectin, and HO-1, all involved in anti-inflammatory response (Fig. 5). Interestingly, Kavain counteracted effects associated with the infection and significantly increased PGC-1α expression (p < 0.05) (6-fold for Kavain) (Fig. 5B). The same beneficial effects of Kavain were also observed for MnSOD, HO-1, and adiponectin mRNA expression (p < 0.05) (Fig. 5C–E). Furthermore, the increase in adiponectin level was confirmed by immunofluorescence (Fig. 6). The same results were observed in primary adipocytes harvested from mouse adipose tissue (Fig. 2).
PGC-1α knockdown prevented Kavain-mediated antioxidative and anti-inflammatory properties
To evaluate the impact of PGC-1α in oxidative stress and inflammatory response in 3T3-L1–derived adipocyte cells, MnSOD, HO-1, and TNF-α mRNA levels were measured in cells in which PGC-1α was knockdown (Fig. 5). The knockdown of PGC-1α decreased MnSOD and HO-1 mRNA and increased TNF-α (p < 0.05). Interestingly, in PGC-1α–inhibited adipocytes, Kavain did not rescue MnSOD or HO-1 mRNA expression levels but also did not reduce TNF-α expression (Fig. 5). These results demonstrated that PGC-1α–related pathways are key elements in anti-inflammatory effects displayed by Kavain.
Kavain treatment reduced inflammation induced by P. gingivalis injection in mouse
To assess the inflammatory effect induced by systemic injection of P. gingivalis on adipocytes, i.p. injection was performed. Isolated primary adipocytes from infected mice exhibited an increased expression of inflammatory markers such as TNF-α, IL-6, NOV, and NF-κB, whereas PGC-1α expression was decreased (Fig. 7). As observed in vitro, treatment with Kavain significantly decreased inflammatory response and restored PGC-1α expression.
In this study, the proinflammatory and pro-oxidative roles of P. gingivalis on adipocytes were studied in an attempt to determine more precisely the relationship between periodontitis and obesity. Moreover, the anti-inflammatory properties of Kavain counteracted such effects and appeared to improve adipogenesis by the disruption of cytokine production and an increase of mitochondrial genes, PGC-1α, and adiponectin levels. To our knowledge, this is the first study to demonstrate a direct effect of P. gingivalis infection on adipocyte inflammation in vivo and that Kavain targets PGC-1α signaling cascade. Furthermore, this process was also related to an increase of antioxidant genes MnSOD and HO-1 expression and inhibition of the progression toward terminal adipocyte differentiation as evidenced by the increase of adiponectin level. These novel findings highlighting Kavain-mediated, PGC-1α adiponectin interplay suggest a prominent role for the modulation of adipocyte maturation in the decrease of P. gingivalis–induced inflammation in adipocytes and in adipose tissues.
The role of infection, mainly associated with bacterial byproducts such as LPS manifested in sustained low chronic inflammation, is considered an important factor in the development of obesity (33). For instance, specific profiles of gut microbiota are associated with increased obesity-related clinical parameters due to activation of specific molecular pathways, resulting in a dysregulated inflammatory response (34). Owing to a reported relationship between periodontitis and obesity, several studies focused on P. gingivalis because of its frequent occurrence in obese patients (35). P. gingivalis, as well as other pathogens from periodontal biofilms, is able to bypass the epithelial barrier of the periodontal pocket, spread within connective tissues, disseminate through blood flow, and overcome the innate immune response, allowing its persistence within cells and contributing to low chronic inflammation at a distance from the source of infection (36). We show in this study that P. gingivalis infection was able to change the inflammatory phenotype of adipocytes characterized by increased TNF-α and IL-6 levels through modulation of NF-κB. This is, to our knowledge, the first demonstration of a direct effect induced by such bacteria in vivo. Such inflammatory response has already been observed in adipocytes stimulated with P. gingivalis LPS (12, 14) and in other cellular models such as macrophages, epithelial cells, and fibroblasts (26, 37). The secretion of TNF-α and IL-6 is of importance in the context of obesity as TNF-α is considered an important paracrine factor contributing to adipocyte insulin resistance through modulation of the NF-κB and JNK signaling pathway and IL-6 is an important determinant of increased obesity-associated cardiovascular risk through C-reactive protein induction and endothelial cell activation, resulting in increased expression of endothelial adhesion molecules and therefore vascular inflammation (38).
We reported that P. gingivalis–induced upregulation of adipogenic markers including FAS, CEBPα, and PPAR-γ, resulting in increased inflammation and oxidative stress in adipocytes. Adipokines are key molecules of adipose tissue homeostasis, and their secretion is regulated by infection-related parameters (39). Bacterial infection can modulate their physiology and alter their function as observed for M. tuberculosis (11). The decreased level of PGC-1α in response to P. gingivalis infection may be a bacterial mechanism to subvert the innate immune response as we observed that the inhibition of PGC-1α significantly increased TNF-α.
Several pharmacological strategies aimed to reduce low chronic inflammation exist that are associated with obesity. In this study, Kavain effects were evaluated with promising results in counteracting the deleterious effects of P. gingivalis infection. This compound reversed adipogenesis and oil droplet formation and decreased proinflammatory cytokine levels, specifically TNF-α, and oxidative stress associated with ROS formation. These anti-inflammatory properties are already well established in different cell types, including in primary macrophages where their use was associated with a decrease of LPS-mediated TNF-α release (16–18). Regarding the reduction of oxidative stress, Kavain induced MnSOD and HO-1 expression, both primary defense mechanisms to counter the adverse effects of oxidative stress. Because of involvement of MnSOD on ROS level in obesity, several therapeutics have already been proposed to restore or enhance SOD activity (40, 41). Then, we can argue that Kavain offers potential as therapeutic approaches to reduce ROS levels in the treatment of obesity and obesity-related disease. Nevertheless, it also improved phosphorylation of IRp972, a marker of insulin sensitivity (23, 25, 27, 32). Such effect should be investigated in the future to determine which pathways are involved. In this aspect, a specific focus should be placed on PPAR-γ and Akt as these molecules have been described to modulate localization and activity of glucose transporters (GLUT-1 and -3) (42) and as Akt is an already described target for Kavain (43).
We report for the first time, to our knowledge, that P. gingivalis induces CCN3/NOV, which is reversed by Kavain. Ablation of NOV decreased fat mass, improved glucose tolerance, improved insulin sensitivity, and decreased proinflammatory cytokines and chemokines in adipose tissues of obese mice (25, 44). Elevated NOV is associated with increased obesity, plasma triglycerides, and C-reactive protein (45). It has also recently been associated with obstructive sleep apnea (46), a clinical syndrome that is strongly associated with obesity, insulin resistance, and cardiometabolic disease.
Prominently, we found that P. gingivalis reduces PGC-1α, MnSOD, HO-1, and adiponectin expression but increased TNF-α generation in adipocyte cells, which is reversed by Kavain. We postulated that Kavain mediated these beneficial effects via increase of PGC-1α signaling pathway. One key finding corroborates this conclusion. When PGC-1α was inhibited, treatment with Kavain induced reduced effects, emphasizing that PGC-1α–related pathways mediated anti-inflammatory and antioxidant effects of Kavain. Recent studies reported that the decrease in PGC-1α levels increased adipocyte hypertrophy, contributing to increased levels of adiposity, inflammation, and generation of ROS, which is also associated with development of metabolic syndrome (25, 29). PGC-1α induction improves inflammation and ROS via induction of HO-1 (47) and improves adipocyte functions and dynamics (20, 34). This is key to the development of new approaches to the treatment of obesity, diabetes, metabolic syndrome, and other obesity-related diseases. Furthermore, the PGC-1α adiponectin–HO-1 module increases MnSOD, which is a critical component to attenuate superoxide-induced damage. PGC-1α–mediated increase of HO-1 and MnSOD was efficiently reduced in PGC-1α–deficient mice, corroborating that HO-1 and MnSOD levels are impaired in PGC-1α–deficient, 3T3-L1–derived adipocytes. Lack of PGC-1α and HO-1–MnSOD contributed to the increase of mitochondrial-derived superoxide formation and ROS (24, 32). As depicted in Fig. 8, exposure of P. gingivalis increased adipogenic FAS, CEBPα, and PPAR-γ expression and decreased expression of PGC-α, HO-1, MnSOD, and adiponectin secretion, contributing to adipocytes dysfunction. The Kavain-mediated stimulation of PGC-1α signaling induced reduction of ROS and proinflammatory molecules TNF-α, NF-κB, and iNOS induction. The finding that Kavain activates PGC-1α and inhibits TNF-α levels that control adipocytes function emphasized these molecules as potential novel pharmacologic targets to attenuate and perhaps reverse adipocyte remodeling induced by P. gingivalis. Hence, Kavain offers a multifactorial clinical approach to the treatment of adiposity and concomitant metabolic disorders (Fig. 8).
This study confirmed the detrimental role of P. gingivalis on adipocyte homeostasis through increased levels of inflammation (TNF-α) and oxidative stress as a result of decreased levels of PGC-1α and adiponectin. Interestingly, anti-inflammatory and antioxidative effects of Kavain are partially dependent of the activation of PGC-1α. Future studies should be expanded to evaluate in vivo the impact of such a drug on obesity-related inflammation as it will result in improved health for the patient. Fewer physician and dentist visits manifested as major savings in health care costs.
This work was supported by National Institutes of Health/National Institute of Dental and Craniofacial Reasearch Grant R01 DE 014079.
The authors have no financial conflicts of interest.